BROMOCRIPTINE INHIBITS THE SEASONALLY OCCURRING OBESITY, HYPERINSULINEMIA, INSULIN RESISTANCE, AND IMPAIRED GLUCOSE-TOLERANCE IN THE SYRIAN-HAMSTER, MESOCRICETUS-AURATUS
BROMOCRIPTINE INHIBITS THE SEASONALLY OCCURRING OBESITY, HYPERINSULINEMIA, INSULIN RESISTANCE, AND IMPAIRED GLUCOSE-TOLERANCE IN THE SYRIAN-HAMSTER, MESOCRICETUS-AURATUS
复制标题
DOI：
10.1016/0026-0495(91)90057-4
复制
发表时间：
1991-06-01
影响因子：
9.8
通讯作者：
MEIER, AH
中科院分区：
文献类型：
--
作者：
CINCOTTA, AH;SCHILLER, BC;MEIER, AH
季节性肥胖高胰岛素血症的雌性叙利亚仓鼠每天注射溴隐亭或盐水，持续 34 天，以测试溴隐亭对身体脂肪储存水平、肝甘油三酯分泌、葡萄糖耐量以及血浆胰岛素和葡萄糖浓度的影响。将溴隐亭对季节性肥胖仓鼠体内脂肪储存水平以及血浆胰岛素和葡萄糖浓度的影响与季节性瘦仓鼠中观察到的体内脂肪、血浆胰岛素和血糖水平进行比较。溴隐亭治疗显着改善了葡萄糖耐受不良，治疗 14 天后，葡萄糖耐受曲线下的总面积和刺激面积减少了 33%。治疗 34 天后，溴隐亭将体内脂肪储存水平降低了 36%，肝脏甘油三酯分泌量降低了 40%，同时食物消耗没有任何变化。此外，溴隐亭使血浆胰岛素水平降低70%，同时略微降低血浆葡萄糖浓度（即胰岛素与葡萄糖的比率降低68%）。溴隐亭对季节性肥胖仓鼠的体脂、血浆胰岛素和血浆胰岛素与葡萄糖比率的降低作用与在季节性瘦仓鼠中观察到的结果相同。昼夜神经内分泌节律的相位关系的变化已被证明可以调节脊椎动物（包括叙利亚仓鼠）的年度代谢周期。溴隐亭的作用也可以解释为这种昼夜节律机制的改变。
Seasonally obese-hyperinsulinemic female Syrian hamsters were injected daily with bromocriptine or saline for a period of 34 days to test for effects of bromocriptine on body fat store levels, hepatic triglyceride secretion, glucose tolerance, and plasma insulin and glucose concentrations. The effects of bromocriptine on body fat store levels, as well as on plasma insulin and glucose concentrations, in seasonally obese hamsters were compared with the levels of body fat, plasma insulin, and plasma glucose observed in seasonally lean hamsters. Bromocriptine treatment substantially improved glucose intolerance and reduced the total and stimulated areas uder the glucose tolerance curve by 33% after 14 days of treatment. After 34 days of treatment, bromocriptine reduced body fat store levels by 36% and hepatic triglyceride secretion by 40% without any concurrent change in food consumption. Furthermore, bromocriptine reduced the plasma insulin level by 70%, while slightly reducing plasma glucose concentration (ie, 68% reduction in the insulin to glucose ratio). The reductions of body fat, plasma insulin, and plasma insulin to glucose ratio produced by bromocriptine in seasonally obese hamsters are equivalent to those observed in seasonally lean hamsters. Shifts in phase relationships of circadian neuroendocrine rhythms have been demonstrated to regulate annual cycles of metabolism in vertebrates, including the Syrian hamster. The effects of bromocriptine can also be explained as an alteration of such a circadian mechanism.